pacibekitug - Tourmaline Bio
Alternative Names: PF-04236921; PF-4236921; TOUR-006Latest Information Update: 13 Aug 2024
At a glance
- Originator Pfizer
- Developer Pfizer; Tourmaline Bio
- Class Anti-inflammatories; Antirheumatics; Cardiovascular therapies; Eye disorder therapies; Monoclonal antibodies
- Mechanism of Action Interleukin 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Cardiovascular disorders; Graves ophthalmopathy; Kidney disorders
- Discontinued Crohn's disease; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 08 Aug 2024 Tourmaline Bio plans a phase III trial for Thyroid Eye Disease (First-line therapy) in second half of 2024 (SC)
- 16 May 2024 Tourmaline Bio plans a phase III trial for Atherosclerotic cardiovascular disease (ASCVD), and other Cardiovascular disorders (SC) in 2025
- 13 May 2024 Phase-II clinical trials in Cardiovascular disorders (SC) before May 2024